TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05862441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV2-SA2
Description: AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SA
Description: Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
Study: NCT00487279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator
Description: ICD(Implantable Cardioverter Defibrillator)

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No Intervention
Study: NCT04344834

Intervention type: DIAGNOSTIC_TEST
Intervention: A questionnaire or scales
Description: A questionnaire or scale to assess the participants mental health.
Study: NCT02873221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Ubrogepant
Description: Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
Study: NCT01205581

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone High Dose Vaccine
Description: Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone High Dose Vaccine
Description: Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone High Dose Vaccine
Description: Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Standard Dose Vaccine
Description: Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Standard Dose Vaccine
Description: Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Standard Dose Vaccine
Description: Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
Study: NCT03645018

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnosis with tomosynthesis
Description: Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
Study: NCT02425072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A plus chemotherapy
Description: NovoTTF-100A System with Physician's Choice Chemotherapy
Study: NCT03007108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood withdrawal
Study: NCT00841373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation
Description: Panretinal Photocoagulation treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation and intravitreal injection of ranibizumab
Description: Panretinal photocoagulation and ranibizumab
Study: NCT03238846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three month dispensing of ART in CARGs
Description: Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six month dispensing of ART in CARGs
Description: Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
Study: NCT00827580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eniluracil
Study: NCT02129218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
Study: NCT03548194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC210
Description: BNC210 300 mg b.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo b.i.d.
Study: NCT03850522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 peptide
Description: PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
Study: NCT00838136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine 25 mg Chewable Tablets
Description: 2 x 25 mg, single-dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal® 25 mg Chewable Tablets
Description: 2 x 25 mg, single-dose fed
Study: NCT01805570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
Study: NCT03815604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent Housing and Support (IHS)
Description: Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent Housing and Support (IHS)
Description: Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residential Care Settings and other Treatment as Usual (RCS/TAU)
Description: Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residential Care Settings and other Treatment as Usual (RCS/TAU)
Description: Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.
Study: NCT01438944

Intervention type: DRUG
Group type: OTHER
Intervention: Nicabate 21mg transdermal NRT
Description: Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
Study: NCT02799290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADIPOSE TISSUE EXTRACT
Description: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLATELET-RICH PLASMA GEL
Description: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
Study: NCT02194088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac and Atropine combination drug
Description: Diclofenac will be associated with a small dose of atropine 1.2mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each capsule of active medication, a capsule of placebo will be provided, identical looking.
Study: NCT01429935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginger powder
Description: capsules contain 500mg Ginger powder,every 6hours,for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: capsules of Ibuprofen 400 mg, every 6 hours for 5 days
Study: NCT03785873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal-Irinotecan
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous (IV) infusion
Study: NCT02502422

Intervention type: DEVICE
Group type: OTHER
Intervention: Classic laryngeal mask airway
Description: 1. measurement of head and neck~   * Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip\~sternal notch), modified mallampati classification under sitting position, thyromental distance.~2. laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~   * # 4.0 for female, #5.0 for male~  * initial cuff volume(air) : maximum volume recommended by the manufacturer~  * check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~  * remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured.
Study: NCT03129438

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: continuous EEG (cEEG)
Description: differential use of continuous versus routine EEG

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: routine EEG (rEEG)
Description: differential use of continuous versus routine EEG
Study: NCT01725763

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Study: NCT05710874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPP-ACP paste
Description: Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPP-ACPF paste
Description: Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.25% fluoride gel
Description: Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional
Description: Twice daily use of conventional toothpaste.
Study: NCT02569489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT02031146

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Study: NCT03505866

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community home-based care intervention
Description: HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
Study: NCT00003641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: Given IV

Intervention type: OTHER
Group type: OTHER
Intervention: observation
Description: Patients undergo observation for 4 weeks.
Study: NCT02438072

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole (10 mg, A02BC01)
Description: The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
Study: NCT03932136

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
Study: NCT01429935

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules contain starch
Study: NCT00795821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 3 tablets QD for 10 weeks
Study: NCT02206893

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring via Smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring via Smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring via Smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring via Smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support via Smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support via Smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional support via Smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional support via Smartphone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring via Web (Static)
Study: NCT03922763

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical cut
Description: Surgeon-derived cut based on patient's anatomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting guide
Description: Angle cut at 132.5 degrees based on cutting guide
Study: NCT01843179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac
Description: Taken orally twice per day at home for 12 months
Study: NCT03499353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALAZOPARIB
Description: Talazoparib 1mg/day
Study: NCT00645853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA INR 2-3
Description: Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
Study: NCT02145273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depression -Group
Study: NCT03406598

Intervention type: OTHER
Intervention: Patients in shock
Description: Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
Study: NCT04221347

Intervention type: OTHER
Intervention: blood sampling
Description: blood samples will be taken in specified time points
Study: NCT03932136

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.
Study: NCT02129218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02129218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Dietary Intervention
Description: Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dietary Intervention
Description: Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified Dietary Intervention
Description: Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
Study: NCT05143801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise with surgical face mask in a temperate environment
Description: Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise with surgical face mask in a hot environment
Description: Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
Study: NCT02129218

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensified Dietary Intervention
Description: Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low glycemic load

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low glycemic load

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medium Glycemic Load

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medium Glycemic Load
Study: NCT00735332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLN-232
Description: 21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
Study: NCT03811600

Intervention type: DIAGNOSTIC_TEST
Intervention: PD1/PD-L1 exosomal expression
Description: exosomal PD1/PD-L1 expression

Intervention type: DIAGNOSTIC_TEST
Intervention: PD1/PD-L1 exosomal expression
Description: exosomal PD1/PD-L1 expression
Study: NCT01525212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-929075
Description: Oral Suspension, ≤ 25 mg, Once daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-929075
Description: Oral Suspension, ≤ 100 mg, Once daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-929075
Description: Oral Suspension, ≤ 400 mg, Once daily, 3 days